With improved therapies, we can reduce the treatment burden of hemophilia A for patients. Here’s my take on how far we have come and where we are going.
Here’s my take on some of the most exciting hemophilia A studies being presented at the upcoming ASH 2019 meeting in Orlando.
What is the role of pharmacokinetic testing? What is the best option for previously untreated patients? Here’s our take.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.